Stanford Health Care’s Janjri Desai, Pharm.D., says pharmacists improve outcomes but often can’t bill for it, making billing parity key to growing services.
|Articles|June 1, 2003
Specialty pharmacies provide pipeline for low-volume, high-cost biotech drugs
Decision to cover self-administered injectables under medical or pharmacy benefit specific to individual plans.
Advertisement
Advertisement
Related to this article
Stanford Health Care’s Janjri Desai, Pharm.D., says pharmacy should be treated as a clinical service line, not just a 340B financial workhorse.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Medicaid can't opt out of gene therapies, so planning matters more, says Katelyn Meyer, Pharm.D. | AMCP Nexus 2026
2
Lower fitness tied to persistent fatty liver disease in teen boys with obesity
3
Updated HIV treatment guidelines address payer barriers and add Bixlenvo
4
How common is atopic dermatitis in the US? Not nearly as common as other research has shown, according to this study
5